Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. - Wikidata - wikimedia - TriplyDB

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

http://www.wikidata.org/entity/Q34364121

about

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Prognostic biomarkers in acute coronary syndrome The Role of Galectin-3 in the Kidneys Macrophages During the Fibrotic Process: M2 as Friend and Foe Cirrhotic cardiomyopathy Statins in heart failure: do we need another trial?Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies State of the Art: Newer biomarkers in heart failure The water network in galectin-3 ligand binding site guides inhibitor design Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy Galectin 3 and incident atrial fibrillation in the community.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation.Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells.Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans.Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.Emerging biomarkers in heart failure and cardiac cachexia Proteomic analysis of meningiomas.Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants.Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.Novel Biomarkers: Utility in Patients with Acute Chest Pain and Relationship to Coronary Artery Disease on Coronary CT Angiography.Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

P2860

Q24649584-54CFA70D-C4D9-48FD-AF53-D3BCEEFFD33E Q24651908-992B0981-67B0-4C37-AEA8-58BEF4BD4694 Q26738521-DB9F62EA-6A8C-4D3C-A191-34772DE59826 Q26752754-CC1A9308-F789-4280-A021-843F106A391B Q26774649-76AD24FC-9343-49AE-A7EF-01837CB22C4F Q26778048-CABE506A-3EE8-47EE-8A04-48825A269AD4 Q26998966-12837690-C37B-4ADB-AEA0-56A26E563C59 Q27002436-3E308460-200F-4C34-B2B8-730593F778BE Q27027899-ED660DF9-2B4D-4F3D-9E13-95FC97EB87FE Q27697923-91DAF6F0-C366-4A2B-827A-83469F8BEAF9 Q28301007-45DCB25A-B148-4AAB-8B95-9667045E81B6 Q33555143-333711E4-EB9F-47EC-8C26-A4E39D0926BA Q33577541-004614D1-DF09-48C4-B779-21A661CF4D51 Q33754895-276136E5-BDCB-4B36-9241-D99C572411EB Q33754984-8545731B-ED63-498A-BCA4-19266E7E621A Q33863482-B8E4BB4A-3F63-4967-8D02-41EE9E0B4928 Q33873592-74661EDA-359F-4386-8F54-91D8C302FD77 Q33897327-0E8019D1-382F-43DF-8AD2-3D87F06A035D Q33912126-E5D3B65F-C59B-4D52-A388-1D3BC6B39288 Q34032111-0780317C-0A7F-4B0E-985A-0C8C01F9BA18 Q34102031-7E13B253-1DBE-4417-A0DE-F248356E584C Q34122713-9946E7A3-4EB8-425B-B9B2-90CEDBBD24F7 Q34269132-5CEF89AE-6C11-4A4D-BB89-C66688F35182 Q34338521-3D4FDDDE-DC97-405E-9071-9EBA8DB10A12 Q34472413-86176888-7B13-48DF-A97C-60F6DB16D9C2 Q34528187-E9F0D2CD-DA8C-46FA-84E8-EFCF8908B1E4 Q34622450-39159BAF-4D73-4957-AF4D-F898D321EDAD Q34836097-CBAA4DAB-C807-4E23-8E9E-10B4F944D3EC Q35004277-3B8DC76C-FDF2-4E86-8841-40B901343A9B Q35007422-F3F7D6F8-2AA3-43B9-8F27-582C421F4D01 Q35025805-EEEA2C15-626A-4CB7-AFBE-584819E90FE5 Q35026202-A9EDAF57-9415-4435-9111-3D791233AF28 Q35070734-FEEFB090-B8BB-40FB-9D53-210390B8C3A4 Q35109460-41D89029-EB31-49A1-A809-F7F1E62957E4 Q35150731-99FBFA0D-3432-4C59-84C9-83110E5DBB58 Q35164124-EEF72E8C-F0B2-4AB0-B636-0BC1B959C09A Q35191679-904F54E4-0903-41C2-84BA-E43117A2DE35 Q35206146-2014E907-876A-4A43-B252-057D1F2BBC13 Q35286926-86F21785-5F57-49B1-81B1-CE4E707D7D63 Q35393885-C3421D79-7136-4B3D-851D-440D13E9BE36

P2860

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

http://www.wikidata.org/entity/Q34364121

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@ast

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@en

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@nl

type

label

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@ast

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@en

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@nl

prefLabel

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@ast

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@en

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@nl

P1433

Q34364121-762A0EDD-5FCF-4F82-BA6E-6F1EAD49CE6C

P1476

Q34364121-3D9D9512-4E30-4A2D-8825-2E7C223AC93E

P2093

Q34364121-112F7001-8BED-4976-B7AC-D5202F69AD96

Q34364121-2BBF96D0-1814-4B3A-A713-A34556108B5C

Q34364121-3DEE6D9E-A519-4A3C-9C80-67EB68BA4DF3

Q34364121-3FCA4A3F-A4BE-4FDB-B6C4-87929284A438

Q34364121-4098160B-0904-4709-86A8-AC86918ADEA1

Q34364121-516832E1-2F79-456A-B92B-0FC4E7E02082

Q34364121-6F1F5603-653C-477D-A568-9A23A2B96727

Q34364121-BB6916D2-C64C-4D9F-85C0-2DDDC75C8214

Q34364121-C803D12F-DB43-46EB-A93D-7C72F9B78052

Q34364121-E3CB8CEE-EA21-417E-8B72-A64D14B7E7D2

P304

Q34364121-AF1E371E-368A-4D24-86D1-51DA2B6C0D83

P31

Q34364121-E9648631-1680-4776-A2B7-5F3572556C4A

P356

Q34364121-1993E115-2CE7-4CEF-B416-971E76404452

P407

Q34364121-BF51655E-A6D2-44D9-AA1D-5FDFEE895291

P433

Q34364121-5368E9EE-9ACF-42EC-9B07-5BC0D17EA872

P478

Q34364121-75EEDD4B-C5E7-4EFF-A551-DF2A5899BFBB

P577

Q34364121-C2AD4492-B76A-4BCE-9EE6-D6C806E5FE94

P5875

Q34364121-50DB2823-C65D-40FA-8BB6-E438078521E9

P698

Q34364121-239D74FD-544C-4501-9683-031C744B0565

P921

Q34364121-0D28E2DB-690C-4F5F-ACEB-3984153433DB

P356

01.CIR.0000147181.65298.4D

P1433

P1476

Galectin-3 marks activated mac ...... ibutes to cardiac dysfunction.

@en

P2093

Blanche Schroen

http://www.w3.org/2001/XMLSchema#string

Hans-J Gabius

http://www.w3.org/2001/XMLSchema#string

Harry J G M Crijns

http://www.w3.org/2001/XMLSchema#string

Jack P M Cleutjens

http://www.w3.org/2001/XMLSchema#string

Jop H van Berlo

http://www.w3.org/2001/XMLSchema#string

Jos Maessen

http://www.w3.org/2001/XMLSchema#string

Sabine André

http://www.w3.org/2001/XMLSchema#string

Saraswati Pokharel

http://www.w3.org/2001/XMLSchema#string

Thomas J van Brakel

http://www.w3.org/2001/XMLSchema#string

Umesh C Sharma

http://www.w3.org/2001/XMLSchema#string

P304

3121-3128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000147181.65298.4D

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8200802

http://www.w3.org/2001/XMLSchema#string

P698

15520318

http://www.w3.org/2001/XMLSchema#string

P921